**Health Canada Stakeholder Engagement Session**

**Comment Form - Discussion Questions: *Preparing for the Future***

Optional Contact Information:

|  |  |
| --- | --- |
| **Name** |  |
| **Title** |  |
| **Organization/Company** |  |
| **Email Address** |  |

Table 1: Comments

|  |  |  |
| --- | --- | --- |
| **Section** | **Question** | **Comments** |
| 1. **Pre-Evidence-based Regulating/Ad hoc Regulation** | 1. **We have heard from various stakeholders that outdated regulatory requirements in the Food and Drug Regulations are posing challenges. If this applies to you, can you identify what requirements in the regulations are of greatest concern and examples of the impact these outdated provisions has had for you or your constituents?** |  |
| 1. **Evidence-based Regulating** | 1. **As we work to consolidate and streamline regulatory requirements for health products in Canada, can you identify some examples of key inefficiencies within the current framework or with respect to international alignment that could be addressed through this process?** |  |
|  | 1. **In your opinion, to what degree is product classification an impediment to innovation? If Health Canada were to advance a more agile classification system to simplify and clarify what requirements apply to a specific product, how might this impact your business practices?** |  |
| 1. **Regulating Advanced Technologies** | 1. **To what extent would you say that advanced technologies are challenging the current health product regulatory frameworks in Canada? Can you share examples of challenges that you, your constituents or others are seeing in this area?** |  |
|  | 1. **What considerations do you think would be important in advancing a new or innovative approach to regulating advanced technologies?** |  |
| 1. **Moving Forward** | 1. **With respect to supporting and reducing barriers to innovative products, what would be the most significant outcome that you would like to see as part of the Regulatory Review and Modernization process?** |  |

**For any questions, please contact Craig Hasilo, Chief Scientific Officer, CellCAN at** [**c.hasilo@cellcan.com**](mailto:c.hasilo@cellcan.com)